ReviewJournal of the Endocrine Society2022
Perioperative Management of Pheochromocytomas and Sympathetic Paragangliomas.
Review in Journal of the Endocrine Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025.Endocrine journal · 2026Guideline
- Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma.Endocrine-related cancer · 2023Pooled it
- Short-term perioperative safety and long-term follow-up after robotic-assisted resection of non-renal, non-adrenal retroperitoneal tumors: a 10-year retrospective cohort study.Translational andrology and urology · 2026Article
- Homeobox genes in endocrine tumorigenesis: mechanisms, tumor microenvironment interaction, and therapeutic potential.Medical oncology (Northwood, London, England) · 2026Review
- Sweet syndrome with reactive lymphadenopathy mimicking metastatic disease in anJCEM case reports · 2026Article
- Diagnostic value of ⁶⁸Ga-DOTATATE PET/CT volumetric parameters in differentiating adrenal lesions.Annals of nuclear medicine · 2026Article
- Diagnosis and Management of Pheochromocytoma in Pregnancy: A Multidisciplinary Approach to Treatment and Outcomes at Mbarara Regional Referral Hospital: A Case Report.International medical case reports journal · 2026Article
- Surgical Management of a Left Main Coronary Trunk-Adjacent Functional Cardiac Paraganglioma Using Proactive Coronary Artery Bypass Grafting: A Case Report.Surgical case reports · 2026Article
- Article
- Update on Systemic Therapies for Metastatic/Unresectable Pheochromocytomas and Paragangliomas and Future Directions.Cancers · 2025Review
- Article
- The Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management.International journal of molecular sciences · 2025Review
- Massive pheochromocytoma causing adrenal crisis during surgery: a case report and review of the literature.Journal of medical case reports · 2025Review
- Successful Management of Infective Endocarditis Complicated by Pheochromocytoma: A Case Report.Cureus · 2025Article
- Multidisciplinary management of a rare case of a large functional paraganglioma in the posterior mediastinum in an adolescent: a case report and literature review.Frontiers in oncology · 2025Article
- An unexpected retroperitoneal paraganglioma with hypertensive crisis during surgical resection: a case report and literature review.Frontiers in oncology · 2025Article
- Case Report: Solving a decade-long paroxysmal hypertension mystery: bladder paraganglioma.Frontiers in oncology · 2025Article
- Cardiogenic shock in phaeochromocytoma multisystem crisis: a case report.European heart journal. Case reports · 2024Article
- Identification of Predictors of Metastatic Potential in Paragangliomas to Develop a Prognostic Score (PSPGL).Journal of the Endocrine Society · 2024Article
- [Personalized treatment of pheochromocytoma].Chirurgie (Heidelberg, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors arising from chromaffin cells of the adrenal medulla or extra-adrenal paraganglia, respectively. PPGLs have the highest degree of heritability among endocrine tumors. Currently, ~40% of individuals with PPGLs have a genetic germline and there are at least 12 different genetic syndromes related to these tumors. Metastatic PPGLs are defined by the presence of distant metastases at sites where chromaffin cells are physiologically absent. Approximately 10% of pheochromocytomas and ~40% of sympathetic paragangliomas are linked to metastases, explaining why complete surgical resection is the first-choice treatment for all PPGL patients. The surgical approach is a high-risk procedure requiring perioperative management by a specialized multidisciplinary team in centers with broad expertise. In this review, we summarize and discuss the most relevant aspects of perioperative management in patients with pheochromocytomas and sympathetic paragangliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.